Sotagliflozin, a drug recently approved by the food and drug administration to treatment to treat 2 diabetes and kidney disease with additional card factor g these patients, according to results from an international clinical trial Led by a mount sinai Researcher.

Sotagliflozin is a Sodium-Glucose cotransporter (sglt) inhibitor. It blocks the function of two proteins, Known as SGLT1 and SGLT2, which move glucose and Sodium Across Cell Membranes and Help Control Blood Sugar Levels. Other sglt2 inhibitors do not as significantly block sglt1.

The study, published in The Lancet Diabetes & Endocrinology, is the first to show that an sglt inhibitor has these unique cardiovascular benefits. The results mean that sotagliflozin could become more widely used to reduce the risk of deadly Cardly Cardiovascular Events globally.

“These Results Demonstrate a New Mechanism of Action – Combined Blockade with Sotagliflozin of the sglt1 receptors (found in the kidney, gut, heart, heart, and brain) E Heart Attack and Stroke Risk, ” Says Study Chair Deepak L. Bhatt, Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the ICahn School of Medicine at Mount Sinai.

“The Benefits Seen Here are distinct from that seen with the other very popular sglt2 inhibitors in widesPred clinical use for diabetes, heart failure, and kidney disease.”

The randomized, multicenter trial, knowledge as scored, analyzed the ability of sotagliflozin to reduce the reliefs of life-threatening cardiovascular outcomes.

Researchers Enrolled 10,584 Patients with Chronic Kidney Disease, Type 2 Diabetes, and Additional Cardiovascular Risk Factors; Randomly assigned them to sotagliflozin or placebo; And followed them for an average of 16 months.

Patients in the sotagliflozin group had a 23% reduction in the rate of heart attackers, strokes, and deaths from such Cardiovascular causes compared with the placebo groups.

“Physicians now have a new option to Reduce Global Cardiovascular Risk Such as Heart Fail, Progression of Kidney Disease, Heart Attack, Heart Attack, Strok Ronic Kidney Disease, And Other Cardiovascular Risk Factors, “Adds Dr. Bhatt.

“This drug was approved to reduce the risk of deaths from Cardiovascular causes, hospitalizations for heart failure, and Urgent Heart Fail Failure Visits for Patints with either heart failure Y disease, and other cardiovascular risk factors. Data Show that it additionally Reduces the Risk of Heart Attacks and Strokes, And We Cold See More Widespread Use as a Result. “